lifileucel | sciencenewsnet.in

Breaking News

Potential of ginsenoside Rg1 to treat aplastic anemia via mitogen activated protein kinase pathway in cyclophosphamide-induced myelosuppression mouse model

Refining adipose-derived stem cell isolation for optimal regenerative therapy

Resilience and challenges: Evaluating the impact of stress conditions on mesenchymal stem cells across different passages

Melatonin-based priming of stem cells to alleviate oxidative stress

Effects of miR-214-5p and miR-21-5p in hypoxic endometrial epithelial-cell-derived exosomes on human umbilical cord mesenchymal stem cells

Efficacy of serum-free cultured human umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis in mice

Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a proliferation-inducing ligand

Yes-associated protein-mediated melatonin regulates the function of periodontal ligament stem cells under oxidative stress conditions

Can We Avert the Looming Food Crisis of Climate Change?

Embedding Owner-Manager Values in the Small and Medium Sized Enterprise Context: A Lockean Conceptualisation

26 Nov, 2024

Sylvester Cancer Adding Cellular Therapy to Its Arsenal Against Metastatic Melanoma

May 1, 2024 sarah JonasAnnouncement

Patients in South Florida with metastatic melanoma will soon have access to tumor-infiltrating lymphocyte therapy, or TIL. The therapy will be available at Sylvester Comprehensive Cancer Center and will be South Florida’s only center offering this treatment.

Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma

February 19, 2024 sarah JonasResearch Results

A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.